NCI Grants Lysin Exclusive Rights to Mesothelin Cancer Immunotoxins
Published Date: 9/10/2025
Notice
Summary
The National Cancer Institute is planning to give Lysin Therapeutics an exclusive license to use their special anti-mesothelin immunotoxins to treat cancers that have mesothelin. This means Lysin can develop and sell new cancer treatments, potentially helping patients with tough-to-treat tumors. The deal could speed up new medicines and impact cancer care soon, with business and health benefits on the horizon.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
NCI plans exclusive license to Lysin
The National Cancer Institute (NCI) is contemplating granting an NCI Exclusive Patent License to Lysin Therapeutics, Inc., a company located in Silver Spring, MD, to practice inventions embodied in the patents listed in the notice's Supplementary Information. This gives Lysin the legal right to develop and commercialize the patented anti-mesothelin immunotoxin inventions listed in that supplement.
Potential new treatments for mesothelin cancers
The license under consideration covers anti-mesothelin immunotoxins for treating mesothelin-expressing cancers. If granted, the license would allow Lysin Therapeutics to develop and sell treatments that use these patented anti-mesothelin immunotoxins for cancers that express mesothelin.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2025-17378, Notice of Lodging of Proposed Second Material Modification to Consent Decree Under Title VI of the Clean Air Act
The Department of Justice is updating a deal with Trident Seafoods to fix problems with their old, leaky refrigeration systems that harm the ozone layer. They’re giving Trident four more years to meet one deadline but also making them upgrade one big fridge early and do extra leak checks. People have 30 days to share their thoughts on these changes before they’re final.
Next: 2025-17380, Charter Amendments, Establishments, Reestablishments, Renewals, and Terminations; Novel and Exceptional Technology and Research Advisory Committee
The NIH is renewing the Novel and Exceptional Technology and Research Advisory Committee to keep advising on cool new biomedical tech. They’re holding a virtual meeting on September 29, 2025, to discuss public involvement in clinical research. This keeps important research moving forward with fresh ideas and public input, all without extra costs to taxpayers.